N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. announced it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis. The study is a multi-center,... Read More

By: Steve Friday March 15, 2013 0 comments Tags: Boulder, Charles Scoggin, cystic fibrosis, N30 Pharmaceuticals, N6022